Multiple centers, prospective, phase II trial of gemcitabine and docetaxel combination chemotherapy in patients with locally advanced/metastatic soft tissue sarcoma or imatinib mesylate refractory advanced/metastatic malignant gastrointestinal stromal tumor

Trial Profile

Multiple centers, prospective, phase II trial of gemcitabine and docetaxel combination chemotherapy in patients with locally advanced/metastatic soft tissue sarcoma or imatinib mesylate refractory advanced/metastatic malignant gastrointestinal stromal tumor

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Docetaxel; Gemcitabine
  • Indications Gastrointestinal stromal tumours; Soft tissue sarcoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2009 Planned end date changed from 1 Apr 2007 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 08 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top